Zefit's Zebrafish Developmental Toxicity Platform 'zDART' LOI Accepted into FDA's ISTAND Program View original image

Zefit, a zebrafish-based preclinical testing company led by CEO Lee Gibaek, announced on October 16 that the U.S. Food and Drug Administration (FDA) had officially accepted a Letter of Intent (LOI) for its proprietary zebrafish embryo-based developmental toxicity assessment platform, zDART.

Zefit's Zebrafish Developmental Toxicity Platform 'zDART' LOI Accepted into FDA's ISTAND Program View original image

In a determination letter dated September 22, the FDA notified Zefit that it had accepted zDART (official name: Zebrafish Embryo Developmental Toxicity Assay; review number: DDT-IST-000080) into the Innovative Science and Technology Approaches for New Drugs (ISTAND) program. According to Zefit, this is the first time worldwide that a zebrafish-based test method has had its LOI accepted and entered the ISTAND qualification review process. zDART is designed to predict the results of rabbit tests in conjunction with existing rat test results. Zefit plans to use it to validate and further develop an alternative testing method that reduces animal use.


ISTAND (Innovative Science and Technology Approaches for New Drugs) is an FDA program that validates and qualifies new drug development tools (DDTs) not covered by existing regulations, including organoids, organs-on-chips, non-mammalian models such as zebrafish, and artificial intelligence (AI). Launched as a pilot program in 2020, it became a permanent program in 2025. Tools that receive qualification can be used by pharmaceutical companies worldwide in drug development and regulatory submissions within their specified scope of use, without separate revalidation by the FDA.


Developmental toxicity assessments of medicines have traditionally relied on tests using two animal species: rats, which are rodents, and rabbits, which are non-rodents. Used alongside rat test results, zDART aims to predict the results of rabbit tests and replace them. Its initial applications will be treatments for serious diseases, including cancer drugs. Zebrafish are vertebrates with genes corresponding to about 70% of human genes. Their major organs form within five days after fertilization, and their transparent bodies make it possible to observe organ development in living specimens. Under the European Union (EU) Directive on the protection of animals used for scientific purposes (2010/63/EU), tests conducted at the early embryonic stage have been treated internationally as alternatives to animal testing.


Animal-testing alternatives accepted into ISTAND to date have mainly been cell- and tissue-level models, such as organs-on-chips and organoids. Zebrafish embryos combine the processing speed of cell models with the whole-body responses of animal models. This allows researchers to assess the development of multiple organs and the absorption, distribution, and metabolism of drugs within a single organism, addressing the limitations of cell models.


The ability to rapidly assess whole-body biological responses at scale, rather than responses in a single organ, at the early screening stage appears to be a competitive advantage that distinguishes zDART from existing cell models.


While preparing a Qualification Plan (QP), the next step in the process, Zefit plans to expand its zebrafish-based alternatives to animal testing by applying the methods validated with zDART to assessments of neurological safety, including the potential of drugs to cause seizures, and cardiotoxicity.


“While organoids and organs-on-chips study responses at the level of a single organ, zebrafish embryos make it possible to analyze together the effects of a drug on the organ systems of an entire organism,” said Lee Gibaek, CEO of Zefit. “This will be a practical alternative that reduces animal use in developmental toxicity assessments, which have relied on rats and rabbits.” He added, “We will diligently complete the QP submission and consultations with the FDA, and expand the validation methods developed for developmental toxicity assessments to neurological and cardiac toxicity testing.”



Founded in 2018 and based in Daegu, Zefit specializes in zebrafish-based preclinical contract research services (CRO) and laboratory automation. The company plans to use this achievement to expand collaboration with pharmaceutical companies and CROs in Korea and abroad.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing